The national law firm of Parker Waichman LLP, advocates for victims of defective drug and medical devices, is warning consumers that generic versions of the Type 2 diabetes drug Actos (pioglitazone), have the same side effects and the same risks of bladder cancer, heart failure and other complications as the brand name version.
Takeda Pharmaceutical and Eli Lilly & Co., manufacturers of Actos, have been named as defendants in numerous lawsuits alleging the drug has caused them to suffer bladder cancer. Last summer the Food and Drug Administration issued a warning that using Actos for one year can significantly increase the risk of bladder cancer. Most recently, a study published in the Journal of the National Cancer Institute said that people who used Actos were two to three times more likely to develop bladder cancer than those taking sulfonylurea.
According to Parker Waichman, Actos has also been linked to congestive heart failure. The national firm also warns that because of the Supreme Court decision in Pliva v Mensing, people taking generic drugs are unable to seek litigation against the drug maker for failing to warn about side effects.
The firm also noted that, thanks to a recent Supreme Court decision, victims of side effects from generic versions of drugs are barred from suing generic drug makers from their injuries, while those injured by the name brand drugs still have a right to pursue legal recourse.